Stanisic S, Cicchetti A, Porta C, Procopio G, Berto P. Cost-effectiveness of cabozantinib in second-line treatment of metastatic renal cell cancer (mRCC) in Italy. Grhta [Internet]. 2018 Jul. 27 [cited 2024 Nov. 21];5(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/434